PubMed COVID-19 Clinical Care

Associations of Mental Health Issues with Health Literacy and Vaccination Readiness against COVID-19 in Long-Term Care Facilities-A Cross-Sectional Analysis

Wednesday, March 27, 2024 - 4:00 AM

Vaccinations against COVID-19 are of the utmost importance in long-term care facilities. During the pandemic, mental health issues increased significantly. This cross-sectional analysis aimed to assess the associations of depression and anxiety with

National Level Cross-Sectional Study on Antibiotic Use in Children during the Pre- and Early COVID-19 Eras

Wednesday, March 27, 2024 - 4:00 AM

This study aimed to investigate national data for a quantitative evaluation of antibiotic usage in Korean children during the pre- and early COVID-19 period. This was a cross-sectional study from 2016 to 2021 of children <18 years, grouped by age (0, 1, 2-4, 5-11, and 12-17 years) and city/province. Systemic antibiotic prescriptions, days of administration, and population by age and region were collected. Days of therapy (DOT)/1000 pediatric inhabitant per day (PID) was used for antibiotic...

AlphaFold2 Reveals Structural Patterns of Seasonal Haplotype Diversification in SARS-CoV-2 Spike Protein Variants

Wednesday, March 27, 2024 - 4:00 AM

The slow experimental acquisition of high-quality atomic structures of the rapidly changing proteins of the COVID-19 virus challenges vaccine and therapeutic drug development efforts. Fortunately, deep learning tools such as AlphaFold2 can quickly

Plasmonic Fluorescence Sensors in Diagnosis of Infectious Diseases

Wednesday, March 27, 2024 - 4:00 AM

The increasing demand for rapid, cost-effective, and reliable diagnostic tools in personalized and point-of-care medicine is driving scientists to enhance existing technology platforms and develop new methods for detecting and measuring clinically

Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19

Wednesday, March 27, 2024 - 4:00 AM

AZD7442 is a combination of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing antibodies, tixagevimab and cilgavimab, developed for pre-exposure prophylaxis (PrEP) and treatment of coronavirus disease 2019 (COVID-19). Using

Exploring healthcare workers' experiences of a simple intervention to reduce their intrusive memories of psychological trauma: an interpretative phenomenological analysis

Wednesday, March 27, 2024 - 4:00 AM

ABSTRACTBackground: Many healthcare workers (HCWs) endured psychologically traumatic events at work during the coronavirus disease 2019 (COVID-19) pandemic. For some, these events are re-experienced as unwanted, recurrent, and distressing intrusive

Post-pandemic respiratory infection trends among Northern Chinese children: Challenges and responses

Wednesday, March 27, 2024 - 4:00 AM

No abstract

First Case of COVID-19-Related Left Ventricular Calcification

Wednesday, March 27, 2024 - 4:00 AM

No abstract

Covid-19: Pfizer vaccine to be available privately at pharmacy chain Boots from April

Wednesday, March 27, 2024 - 4:00 AM

No abstract

Agonists or positive allosteric modulators of alpha7 nicotinic acetylcholine receptor prevent interaction of SARS-Cov-2 receptor-binding domain with astrocytoma cells

Wednesday, March 27, 2024 - 4:00 AM

SARS-Cov-2, the virus causing COVID-19, penetrates host target cells via the receptor of angiotensin-converting enzyme 2 (ACE2). Disrupting the virus interaction with ACE2 affords a plausible mechanism for prevention of cell penetration and